Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

11. Juni 2026 07:30 ET | Quelle: Medicus Pharma Ltd

Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program

PHILADELPHIA, June 11, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development...
08. Juni 2026 07:30 ET | Quelle: Medicus Pharma Ltd

Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission

PHILADELPHIA, June 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development...
03. Juni 2026 08:00 ET | Quelle: Medicus Pharma Ltd

Medicus Pharma Advances SkinJect® into Registrational Development for Gorlin Syndrome

PHILADELPHIA, June 03, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development...
28. Mai 2026 08:00 ET | Quelle: Medicus Pharma Ltd

Medicus Pharma Announces $22 Million Non-Dilutive Financing

PHILADELPHIA, May 28, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs...
14. Mai 2026 16:30 ET | Quelle: Medicus Pharma Ltd

Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

PHILADELPHIA, May 14, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs...
06. Mai 2026 07:30 ET | Quelle: Medicus Pharma Ltd

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

PHILADELPHIA, May 06, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs...
27. April 2026 07:30 ET | Quelle: Medicus Pharma Ltd

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

PHILADELPHIA, April 27, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development...
17. April 2026 07:30 ET | Quelle: Medicus Pharma Ltd

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

PHILADELPHIA, April 17, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development...
15. April 2026 07:30 ET | Quelle: Medicus Pharma Ltd

Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression

PHILADELPHIA, April 15, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development...
06. April 2026 07:30 ET | Quelle: Medicus Pharma Ltd

Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention

PHILADELPHIA, April 06, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development...

Nächste Seite